WanYuKuan

Wanyukuan is a China-based biotechnology company specializing in the field of targeted protein degradation (TPD). The company focuses on developing next-generation PROTAC (Proteolysis-targeting chimera) therapeutics to address challenging and previously "undruggable" targets in oncology and other therapeutic areas. By leveraging its proprietary discovery platform, Wanyukuan designs small molecules that recruit E3 ubiquitin ligases to specific disease-associated proteins, leading to their degradation via the proteasome. The firm has attracted significant investment from prominent venture capital firms, including Sequoia China and GL Ventures, to advance its early-stage pipeline toward clinical trials. Wanyukuan's research is centered on identifying novel E3 ligase ligands and optimizing the degradation efficiency of its drug candidates. The company aims to provide transformative treatment options for patients with various cancers and other complex diseases.